Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

نتائج البحث

Display Settings
النتائج لكل صفحة: 10
Sort By: Relevance
Filter
  • 1-8 ل  8 نتائج ل ""Alirocumab""

فلترة النتائج

Publication : cardiovascular diabetology
إعادة تعيين خيارات الفبترة
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.

  • Authors : Colhoun HM; The Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK. .; Leiter LA

Subjects: PCSK9 Inhibitors*; Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*therapeutic use ; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*therapeutic use

  • Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2020 Feb 08; Vol. 19 (1), pp. 14. Date of Electronic Publication: 2020 Feb 08.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

Subjects: Non-HDL-C; lcsh:Diseases of the circulatory (Cardiovascular) system; Time Factors

  • Source: Cardiovascular Diabetology, Vol 16, Iss 1, Pp 1-10 (2017)Cardiovascular diabetology 16(1), 70 (2017).

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.

  • Authors : Ray KK; Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, Kensington, London, SW7 2AZ, UK. .; Del Prato S

Subjects: Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*therapeutic use ; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*therapeutic use ; Atherosclerosis/Atherosclerosis/Atherosclerosis/*drug therapy

  • Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2019 Nov 09; Vol. 18 (1), pp. 149. Date of Electronic Publication: 2019 Nov 09.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×

Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus

Subjects: Male; medicine.medical_specialty; Serine Proteinase Inhibitors

  • Source: Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-15 (2021)Cardiovascular Diabetology

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7.

  • Authors : Chen W; Cancer Institute, Department of Orthopaedics, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao Cancer Institute, Qingdao, 266071, Shandong, China.; Wu X

Subjects: MicroRNAs*/MicroRNAs*/MicroRNAs*/genetics ; Atherosclerosis*/Atherosclerosis*/Atherosclerosis*/genetics; Humans

  • Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Jan 09; Vol. 23 (1), pp. 21. Date of Electronic Publication: 2024 Jan 09.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes.

  • Authors : González-Lleó AM; Sección de Endocrinología y Nutrición. Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria (CHUIMI), Las Palmas de Gran Canaria, España. .; Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, España. .

Subjects: Prediabetic State* ; Diabetes Mellitus*/Diabetes Mellitus*/Diabetes Mellitus*/diagnosis ; Diabetes Mellitus*/Diabetes Mellitus*/Diabetes Mellitus*/drug therapy

  • Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Jan 03; Vol. 23 (1), pp. 4. Date of Electronic Publication: 2024 Jan 03.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis.

  • Authors : Wang X; West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, People's Republic of China.; Wen D

Subjects: Anticholesteremic Agents*/Anticholesteremic Agents*/Anticholesteremic Agents*/adverse effects ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/chemically induced ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/diagnosis

  • Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2022 Jun 15; Vol. 21 (1), pp. 107. Date of Electronic Publication: 2022 Jun 15.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.

  • Authors : Fischer LT; Division of Endocrinology and Diabetology, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.; Hochfellner DA

Subjects: PCSK9 Inhibitors*; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*therapeutic use ; Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*prevention & control

  • Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2021 Apr 24; Vol. 20 (1), pp. 89. Date of Electronic Publication: 2021 Apr 24.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
  • 1-8 ل  8 نتائج ل ""Alirocumab""